Full Federal Circuit Rejects Biogen’s Appeal Over Multiple Sclerosis Drug

shot by IP News Shots / 6:19 pm on 21 December, 2020

An en banc appeal for a review of patent claim invalidation decision by Biogen Inc. has been rejected by the Court of Appeals for the Federal Circuit (CAFC). The earlier ruling had invalidated claims of a patent for Biogen’s multiple sclerosis treatment, Avonex. Biogen had originally accused EMD Serono Inc. and Pfizer Inc. of patent infringement for the patent in suit.

Read More at: https://www.law360.com/trials/articles/1339297/full-fed-circ-won-t-take-up-biogen-appeal-over-ms-drug

Industry: Pharmaceuticals | Type of IP: Litigations